ESTRO 2024 - Abstract Book

S2314

Clinical - Urology

ESTRO 2024

Conclusion:

Dose escalation offers potential benefits for prostate cancer treatment outcomes. This study demonstrates the dosimetric feasibility of ultra-hypofractionated dose escalation to IPL up to 40 Gy in 5 fractions using a 1.5T MR Linac. Findings strongly indicate the need for conducting clinical trials to rigorously evaluate the clinical advantages and safety profile of this dose escalation strategy in prostate cancer treatment.

Keywords: Prostate Cancer, Radiotherapy, Dose escalation